McKesson’s 41% distribution share, specialty-led earnings growth, $5.4 billion free cash flow, and discounted 19.8x forward P/E support a defensive compounder thesis.
McKesson Corporation is an essential cornerstone of the global healthcare infrastructure, acting as a critical logistical, financial, and clinical intermediary in the pharmaceutical and medical supply chains [cite: 1]. The company operates as a key middleman in a highly consolidated U.S. drug distribution system, capturing a persistent spread on massive, high-velocity transactional volume [cite: 2, 3, 4]. The business is structured around four primary reporting segments: North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions [cite: 3, 5]. Through these divisions, McKesson manages the secure distribution of generic, branded, and specialty pharmaceuticals, provides sophisticated clinical support platforms, and delivers medical-surgical supplies to acute and non-acute care settings across North America [cite: 6, 7, 8].
The primary revenue engine is the North American Pharmaceutical segment, which distributes brand-name, generic, and specialty drugs to retail national accounts, healthcare systems, and independent pharmacies [cite: 5, 6, 9]. Geographically, McKesson has streamlined its operations to focus on North America, completing a series of international divestitures to exit its lower-margin retail and wholesale presence in Europe [cite: 10, 11]. This multi-year transformation culminated in the sale of its retail and distribution businesses in Norway on January 30, 2026, marking its complete exit from the European continent [cite: 11]. In Canada, McKesson retains a strong distribution footprint despite previous divestitures of its Rexall and Well.ca retail units, optimizing its capital allocation toward pure-play wholesale distribution [cite: 12, 13].
McKesson's high-velocity revenue engine operates across a diverse customer base, serving retail national pharmacy chains, independent pharmacy groups, institutional hospital networks, community physician offices, and clinical research facilities [cite: 5, 7, 8]. Its most critical commercial relationship is its long-standing partnership with CVS Health to distribute pharmaceuticals to mail-order, specialty, and retail pharmacies, which was extended through June 2027 [cite: 14].
The alternate-site medical supply market is served by the Medical-Surgical Solutions segment [cite: 8]. To optimize corporate focus and unlock significant capital, McKesson finalized a strategic transaction on June 1, 2026, selling a 13% minority stake in its Medical-Surgical Solutions business to funds managed by affiliates of Apollo Global Management for $1.25 billion in convertible preferred equity [cite: 1, 15]. This transaction establishes an enterprise valuation of approximately $13 billion for the unit and serves as a major milestone toward carving the business out into an independent, publicly traded entity via an initial public offering (IPO) [cite: 1, 15].
McKesson remains a preferred partner for healthcare providers and pharmaceutical manufacturers due to its absolute scale and operational efficiencies [cite: 2]. Customers choose McKesson over alternatives due to its robust distribution infrastructure, absolute delivery reliability, and strict adherence to complex safety regulations like the federal Drug Supply Chain Security Act (DSCSA) [cite: 2, 7]. Its proprietary digital healthcare ecosystems and clinical oncology networks further entrench client relationships, establishing high systemic switching costs that generic competitors cannot easily duplicate [cite: 2, 16].
McKesson's financial engine is driven by the steady, non-cyclical demand for pharmaceuticals, coupled with a secular trend toward high-value, complex specialty medications [cite: 4, 17]. The business operates as a vital link between drug manufacturers and dispensing endpoints [cite: 1]. Its physical product lines encompass branded therapeutics, specialty biologics, generic formulations, biosimilars, over-the-counter clinical goods, and medical-surgical supplies [cite: 6, 7, 9].
Top-line revenue is driven by prescription volume expansion, which is supported by an aging North American demographic profile and the rapid introduction of complex therapeutics [cite: 7, 17]. This trend is illustrated by the "GLP-1 revolution" (weight-loss and diabetes treatments like Wegovy and Zepbound), which represents a high-volume, low-margin distribution channel [cite: 3]. In the third quarter of fiscal 2026 alone, McKesson captured $14 billion in GLP-1 distribution revenues [cite: 3].
Gross profit growth is increasingly driven by specialty services, community-based clinical networks, and digital healthcare platforms [cite: 6, 18]. Within the Oncology and Multispecialty segment, the company leverages its provider solutions to distribute high-cost oncology therapeutics directly to community clinics [cite: 6]. This business has been expanded through strategic acquisitions, including a controlling interest in Florida Cancer Specialists & Research Institute's Core Ventures, and the integration of PRISM Vision Group, which extends its clinical network into ophthalmology practices [cite: 19, 20].
The Prescription Technology Solutions segment monetizes clinical software and transactional access tools, including CoverMyMeds [cite: 3, 6]. This segment acts as a digital bridge between manufacturers, payers, and pharmacies, automating prior authorization workflows to prevent prescription abandonment and capture high-margin software revenues [cite: 3, 6, 19].
McKesson's sustainable competitive advantage is supported by three primary structural moats:
The addressable market for healthcare distribution in North America is vast and expanding [cite: 4]. The U.S. pharmaceutical distribution market is valued in excess of $500 billion, growing in the mid-single digits annually due to brand drug price inflation and rising volume demands [cite: 4]. In addition, the auxiliary digital health and clinical software market represents a high-margin opportunity [cite: 23]. The global digital health market is projected to grow from $491.62 billion in 2026 to $2.35 trillion by 2034, representing a 5-year CAGR of 21.60% [cite: 23].
McKesson's primary competition resides within the industry's wholesale oligopoly [cite: 16]. The company competes against Cencora and Cardinal Health on scale, reliability, and contract terms [cite: 2].
| Metric / Dimension | McKesson (MCK) | Cencora (COR) | Cardinal Health (CAH) |
|---|---|---|---|
| Market Position | Scale Leader (~41% US Share) [cite: 3] | Specialty Peer (~35% US Share) [cite: 3] | Diverse Supplies (~22% US Share) [cite: 3] |
| Strategic Advantage | Domestic oncology networks and healthcare technology platforms [cite: 3, 16] | Global manufacturer networks and specialized biopharma services [cite: 2, 16] | Nuclear medicine, precision health diagnostics, and clinical supply bundles [cite: 16, 17] |
| Growth Footprint | Domestic pharmaceutical wholesale optimization and clinical expansions [cite: 11, 24] | Specialty clinical integrations [cite: 16] | Turnaround focused on precision health and nuclear diagnostics [cite: 16, 17] |
McKesson appears to be holding, if not gaining, structural ground [cite: 16]. The company secured the large OptumRx distribution contract, which previously sat with Cardinal Health, driving volume expansion in its core segment [cite: 16]. While Cencora has expanded globally, McKesson's decision to divest lower-margin European operations allows it to reinvest cash into high-margin domestic specialty markets [cite: 11, 16, 24]. This strategy is evidenced by its oncology networks directly competing for physician affiliations with Cencora, positioning McKesson to capture a high share of complex, higher-margin specialty pharmaceutical flows [cite: 16].
McKesson's latest reported financial results are for the fourth quarter and full fiscal year ended March 31, 2026, which were announced on May 7, 2026 [cite: 9, 10].
For the fourth quarter of fiscal 2026, consolidated revenues were $96.3 billion, an increase of 6% year-over-year [cite: 9]. This top-line result missed the analyst consensus estimate of $101.23 billion by approximately 4.9% [cite: 9]. This revenue shortfall was primarily due to lower contributions from branded pharmaceuticals in the North American Pharmaceutical segment [cite: 6] and normalizing volumes in the ambulatory care channel within Medical-Surgical Solutions [cite: 5, 11]. However, the company exceeded bottom-line projections: fourth-quarter adjusted diluted EPS was $11.69, beating the analyst consensus expectation of $11.57 by $0.12, driven by strong growth in specialty product distribution and lower tax and share counts [cite: 6, 9]. On a GAAP basis, fourth-quarter diluted EPS was $13.71, up $3.70 from the prior year period [cite: 6].
For the full fiscal year ended March 31, 2026, McKesson delivered strong performance [cite: 7]. Full-year consolidated revenues rose 12% to $403.4 billion [cite: 7, 25]. Full-year GAAP diluted EPS increased by $12.66 to $38.38 [cite: 6]. Full-year adjusted diluted EPS grew 18% to $39.11, compared to $33.05 in fiscal 2025, exceeding the company’s long-term target growth ranges [cite: 11]. The company generated $6.2 billion in cash flow from operations, with capital expenditures of $745 million resulting in free cash flow of $5.4 billion [cite: 11, 25].
Full-Year Fiscal 2026 Consolidated Results Table:
┌──────────────────────────────┬──────────────────────────────┐
│ Metric │ Value │
├──────────────────────────────┼──────────────────────────────┤
│ Consolidated Revenues │ $403.4 Billion (+12% YoY) │
│ GAAP Diluted EPS │ $38.38 │
│ Adjusted Diluted EPS │ $39.11 (+18% YoY) │
│ Cash Flow from Operations │ $6.2 Billion │
│ Free Cash Flow (Non-GAAP) │ $5.4 Billion │
└──────────────────────────────┴──────────────────────────────┘
In its May 7, 2026 earnings announcement, McKesson established its adjusted diluted EPS guidance range for fiscal year 2027 at $43.80 to $44.60, representing a forecasted growth of 12% to 14% [cite: 6, 9]. The midpoint of $44.20 compares favorably to the fiscal 2026 baseline of $39.11 [cite: 9]. Management reaffirmed its long-term financial growth targets, aiming for sustained long-term adjusted EPS expansion of 13% to 16% [cite: 6].
Key strategic steps outlined by management included the planned separation of the Medical-Surgical division to maximize shareholder value, expanding community care networks, and the transition of key financial leadership [cite: 10, 26]. long-time CFO Britt J. Vitalone retired on May 28, 2026, and was succeeded by Kenny K. Cheung, who was appointed as Executive Vice President and Chief Financial Officer [cite: 27, 28].
McKesson’s shares declined by approximately 2% immediately following the Q4 results, driven by the top-line revenue miss and a moderated revenue forecast for fiscal 2027 [cite: 9, 29, 30]. However, long-term sentiment remained positive [cite: 29]. Analysts focused on the company's strong EPS performance, cash flow, and guidance [cite: 9, 29].
Following the report and subsequent corporate actions—including a 15% increase in the quarterly dividend to $0.94 per share on July 22, 2026 [cite: 31, 32]—major Wall Street firms reaffirmed positive recommendations [cite: 33]. Citi maintained a Buy rating with a target price of $1,000, TD Cowen maintained Buy at $989, and J.P. Morgan reiterated a Buy rating with a target of $1,015, highlighting McKesson’s strong market position and capital allocation strategy [cite: 33].
Analyst Price Targets Post-Q4 Earnings (May-July 2026):
┌───────────────────────────┬───────────────────────────┬───────────────────────────┐
│ Analyst Firm │ Rating │ Target Price (USD) │
├───────────────────────────┼───────────────────────────┼───────────────────────────┤
│ J.P. Morgan │ Buy │ $1,015.00 [cite: 33] │
│ Citi │ Buy │ $1,000.00 [cite: 33] │
│ TD Cowen │ Buy │ $989.00 [cite: 33] │
│ Morgan Stanley │ Buy │ $966.00 [cite: 33] │
│ Robert W. Baird │ Buy │ $941.00 [cite: 33] │
│ Mizuho Securities │ Hold │ $885.00 [cite: 33] │
│ Wells Fargo │ Hold │ $812.00 [cite: 33] │
└───────────────────────────┴───────────────────────────┴───────────────────────────┘
McKesson’s valuation is defined by its high-velocity, low-margin business model [cite: 4]. Traditional metrics like Price-to-Sales (P/S) are low (~0.2x to 0.3x) because of the company's massive revenue base [cite: 30]. However, the business is better evaluated on a Price-to-Earnings (P/E) and Price-to-Free Cash Flow (P/FCF) basis [cite: 30].
McKesson trades at an adjusted forward P/E of approximately 19.8x, which is a discount to the broader healthcare sector average of roughly 24.9x [cite: 29]. This relative undervaluation does not fully reflect the stability of its cash generation [cite: 29, 34].
The primary financial drivers supporting this valuation are:
* Top-Line Revenue Expansion: Over the past five fiscal years, McKesson's revenue expanded at a CAGR of 10.2% [cite: 21], supported by drug volume demand and specialty pharmaceutical growth [cite: 3, 4].
* Aggressive Share Count Reductions: Due to its consistent cash generation, McKesson has repurchased a significant number of shares [cite: 4]. Outstanding shares decreased from 150 million in fiscal 2021 to 120 million in early fiscal 2026, representing a 5-year CAGR of -5.3% in share reduction [cite: 21, 35]. In April 2026, the board approved an additional $5.0 billion repurchase authorization, bringing total authorized buybacks to $7.7 billion [cite: 9, 11]. This repurchasing activity provides a strong tailwind to EPS growth [cite: 35].
* High Free Cash Flow Conversion: McKesson converted $5.4 billion of its fiscal 2026 earnings into free cash flow [cite: 11], requiring low capital expenditures (historically below 0.2% of revenue) to sustain its national logistics network [cite: 11, 21].
The transition of the Chief Financial Officer role to Kenny K. Cheung introduces transition risks [cite: 27, 28]. Although Cheung has extensive finance leadership experience, including CFO roles at Sysco and Hertz, managing McKesson's working capital model requires careful execution [cite: 27]. Additionally, the planned separation of the Medical-Surgical division via a standalone IPO involves operational complexities, and its completion is subject to market conditions [cite: 1].
Competitive pressures include emerging direct-to-consumer and transparent pricing platforms, such as the Mark Cuban Cost Plus Drug Company, which operate under a flat 15% markup to bypass traditional wholesale distribution [cite: 16]. While these models lack the scale to match McKesson’s distribution network, persistent market share gains could pressure industry margins over time [cite: 2, 16]. Additionally, vertically integrated competitors like CVS Health, which owns Aetna and Caremark, could prioritize internal clinical margins over external wholesale channels, squeezing distribution spreads [cite: 16].
McKesson faces customer concentration risk, particularly from its primary distribution agreement with CVS Health, which runs through June 2027 [cite: 4, 14, 36]. CVS represents a significant portion of McKesson's revenues and U.S. Pharmaceutical distribution volumes [cite: 36]. Any material failure to renew this contract on comparable economic terms would impact McKesson's long-term top-line and margin stability [cite: 4, 14].
Despite entering into a comprehensive $26 billion national opioid settlement in 2022 alongside Cardinal Health and Cencora, McKesson remains subject to structural cash outflows [cite: 37, 38]. The company is responsible for contributing up to $7.4 billion over an 18-year period [cite: 38]. Individual non-participating states, such as Washington, also have separate settlement obligations ($518 million shared payout paid over 17 years) that continue to impact cash outflows [cite: 39].
Furthermore, federal pricing interventions under the Inflation Reduction Act (IRA) and adjustments to the 340B Drug Pricing Program could compress absolute brand drug prices, reducing the ad valorem distribution margins McKesson collects on those products [cite: 30, 40].
McKesson carries a deficit in total stockholder equity (-$2.07 billion as of late 2025/early 2026), driven by its aggressive treasury stock buyback strategy [cite: 4, 41]. While this capital allocation strategy has supported return on equity, it distorts traditional leverage metrics [cite: 4]. McKesson also maintains a tight short-term liquidity profile with a current ratio below 1.0, a standard trait in the wholesale distribution sector that relies on rapid inventory turnover and managing supplier payment terms [cite: 4, 21]. If working capital cycles slow or interest rates rise significantly, the cost of financing short-term receivables could increase, impacting net interest margins [cite: 4, 21].
This quantitative scenario model projects McKesson's potential 5-year equity returns (FY2027–FY2031), using the fiscal year 2026 baseline revenue of $403.43 billion [cite: 25] and a late July 2026 close price of $856.19 [cite: 43, 44].
The scenario projections are calculated using the following equations:
$\text{Projected Year 5 Revenue } (Rev_{Y5}) = Rev_{FY26} \times (1 + g)^5$
$\text{Projected Year 5 Net Income } (NI_{Y5}) = Rev_{Y5} \times NetMargin_{Adj}$
$\text{Projected Year 5 Share Count } (Shares_{Y5}) = Shares_{Current} \times (1 - d)^5$
$\text{Projected Year 5 EPS } (EPS_{Y5}) = \frac{NI_{Y5}}{Shares_{Y5}}$
$\text{Projected Share Price } (P_{Y5}) = EPS_{Y5} \times Multiple_{Exit}$
The Base Case assumes that McKesson maintains its market position, with stable demand for branded, generic, and specialty pharmaceuticals [cite: 4].
* Revenue Growth: Assumes a 5-year revenue CAGR of 6.5%, supported by specialty medicine growth and generic volumes [cite: 17, 18], yielding Year 5 revenue of $552.73 billion [cite: 45].
* Net Profit Margin: Assumes net profit margins hold steady at 1.30%, as higher-margin oncology and technology solutions offset traditional wholesale margin pressures [cite: 18, 45].
* Projected Year 5 Net Income: Calculated as $\$552.73B \times 1.30\% = \$7.185B$ ($7,185.49 million) [cite: 45].
* Share Count: Assumes McKesson continues to reduce its outstanding shares by an average of 3.0% annually, lowering the share count from 120.0 million to 103.05 million over five years [cite: 21, 45].
* Implied Year 5 EPS: Projected at $\$7,185.49M / 103.05M = \$69.72$ per share [cite: 45].
* Valuation Multiple: Assumes an exit adjusted P/E multiple of 18.0x [cite: 45].
* Implied Share Price Year 5: Calculated as $\$69.72 \times 18.0 = \$1,255.02$ [cite: 45].
* Estimated Returns: Yields a 5-year total return of +46.6% and an annualized return of +7.9% [cite: 45].
The High Case assumes accelerated expansion in high-margin oncology and specialty biopharma solutions [cite: 10].
* Revenue Growth: Assumes a 5-year revenue CAGR of 8.5%, driven by higher specialty volumes and market share gains, yielding Year 5 revenue of $606.62 billion [cite: 3, 45].
* Net Profit Margin: Assumes net profit margins expand to 1.45% due to higher technology segment contributions [cite: 3, 45].
* Projected Year 5 Net Income: Calculated as $\$606.62B \times 1.45\% = \$8.796B$ ($8,795.99 million) [cite: 45].
* Share Count: Assumes share repurchases accelerate to a 4.5% annual reduction rate, lowering outstanding shares to 95.32 million [cite: 45].
* Implied Year 5 EPS: Projected at $\$8,795.99M / 95.32M = \$92.28$ per share [cite: 45].
* Valuation Multiple: Assumes a multiple expansion to 20.0x exit P/E [cite: 45].
* Implied Share Price Year 5: Calculated as $\$92.28 \times 20.0 = \$1,845.58$ [cite: 45].
* Estimated Returns: Yields a 5-year total return of +115.6% and an annualized return of +16.6% [cite: 45].
The Low Case assumes a customer loss or pricing pressure in generic distribution [cite: 4, 14].
* Revenue Growth: Assumes a 5-year revenue CAGR of 3.5%, yielding Year 5 revenue of $479.15 billion [cite: 14, 45].
* Net Profit Margin: Assumes profit margins compress to 1.05% due to logistics inflation and pricing pressure [cite: 5, 45].
* Projected Year 5 Net Income: Calculated as $\$479.15B \times 1.05\% = \$5.031B$ ($5,031.08 million) [cite: 45].
* Share Count: Assumes share repurchases slow to a 1.5% annual reduction rate, resulting in 111.27 million outstanding shares [cite: 45].
* Implied Year 5 EPS: Projected at $\$5,031.08M / 111.27M = \$45.21$ per share [cite: 45].
* Valuation Multiple: Assumes the P/E multiple compresses to 14.0x [cite: 45].
* Implied Share Price Year 5: Calculated as $\$45.21 \times 14.0 = \$632.96$ [cite: 45].
* Estimated Returns: Yields a 5-year total return of -26.1% and an annualized return of -5.9% [cite: 45].
The following table models the projected share price trajectory across the three cases over the five-year investment horizon:
| Scenario | Year 0 (Current) | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 (Implied) |
|---|---|---|---|---|---|---|
| High Case | $856.19 [cite: 43] | $998.00 | $1,164.00 | $1,357.00 | $1,582.00 | $1,845.58 [cite: 45] |
| Base Case | $856.19 [cite: 43] | $924.00 | $997.00 | $1,076.00 | $1,161.00 | $1,255.02 [cite: 45] |
| Low Case | $856.19 [cite: 43] | $806.00 | $758.00 | $713.00 | $671.00 | $632.96 [cite: 45] |
Using these probability weights, the probability-weighted fair value target for McKesson in five years is:
$\text{Projected Fair Value Share Price} = (0.60 \times \$1,255.02) + (0.25 \times \$1,845.58) + (0.15 \times \$632.96) = \$1,309.35$ [cite: 45]
This probability-weighted model implies a projected 5-year fair value of $1,309.35, representing a potential total return of +52.9% and an annualized return of +8.9% [cite: 45].
| Scenario | Revenue in Year 5 | Margin / Earnings Assumption | Valuation Multiple Assumption | Current Share Price | Implied Future Share Price | 5-Year Total Return | Annualized Return | Probability |
|---|---|---|---|---|---|---|---|---|
| High Case | $606.62 Billion [cite: 45] | 1.45% Margin / $92.28 EPS [cite: 45] | 20.0x P/E [cite: 45] | $856.19 [cite: 43] | $1,845.58 [cite: 45] | +115.6% [cite: 45] | +16.6% [cite: 45] | 25% [cite: 45] |
| Base Case | $552.73 Billion [cite: 45] | 1.30% Margin / $69.72 EPS [cite: 45] | 18.0x P/E [cite: 45] | $856.19 [cite: 43] | $1,255.02 [cite: 45] | +46.6% [cite: 45] | +7.9% [cite: 45] | 60% [cite: 45] |
| Low Case | $479.15 Billion [cite: 45] | 1.05% Margin / $45.21 EPS [cite: 45] | 14.0x P/E [cite: 45] | $856.19 [cite: 43] | $632.96 [cite: 45] | -26.1% [cite: 45] | -5.9% [cite: 45] | 15% [cite: 45] |
| Weighted | — | — | — | $856.19 [cite: 43] | $1,309.35 [cite: 45] | +52.9% | +8.9% | 100% |
STABLE CAPITAL RECYCLER
This scorecard evaluates McKesson's qualitative drivers on a 1-10 scale:
Management Alignment ■■■■■■■■□□ (8/10)
Revenue Quality ■■■■■■■□□□ (7/10)
Market Position ■■■■■■■■■□ (9/10)
Growth Outlook ■■■■■■■■□□ (8/10)
Financial Health ■■■■■■□□□□ (6/10)
Business Viability ■■■■■■■■■□ (9/10)
Capital Allocation ■■■■■■■■■□ (9/10)
Analyst Sentiment ■■■■■■■■□□ (8/10)
Profitability ■■■■■□□□□□ (5/10)
Track Record ■■■■■■■■■□ (9/10)
──────────────────────────────────────────
OVERALL BLENDED SCORE: ■■■■■■■■□□ (7.8/10)
DEFENSIVE SCALE COMPOUNDER
McKesson Corporation represents a defensive, cash-generative investment opportunity within the healthcare sector [cite: 4]. The company operates as a key infrastructure provider in the pharmaceutical value chain, capturing stable, high-velocity distribution volumes [cite: 3]. Although traditional wholesale margins remain thin [cite: 4], McKesson has successfully expanded into higher-margin adjacencies, specifically through its domestic Oncology and Prescription Technology Solutions networks [cite: 6, 18].
The primary catalysts supporting a potential rerating include:
1. The strategic separation and public spinoff of its Medical-Surgical division to simplify corporate structure and unlock capital [cite: 1].
2. Ongoing margin expansion driven by therapeutic developments in community-based specialty care, oncology, and retina practices [cite: 6, 19].
3. High-volume logistical tailwinds from the GLP-1 therapeutic expansion [cite: 3].
4. Aggressive share repurchase activity, supported by $5.4 billion in annual free cash flow and a newly expanded $7.7 billion buyback authorization [cite: 9, 11].
These opportunities are balanced by key risks:
1. The structural contract renewal with CVS Health in June 2027 [cite: 14].
2. Industry price compression pressures from federal drug price negotiations under the IRA [cite: 5, 30].
3. Execution risks associated with the ongoing CFO transition [cite: 27, 28].
Overall, McKesson's dominant ~41% market share in a highly protected oligopoly makes it an attractive defensive holding, offering stable cash-generation and solid capital recycling potential through economic cycles [cite: 3, 4].
ASYMMETRIC LOGISTICAL TOLLBOOTH
McKesson's stock has demonstrated solid structural performance, trading in late July 2026 at approximately $856.19 [cite: 43]. This price level remains above its key 200-day simple moving average of $835.44, indicating a supportive long-term bullish trend [cite: 22]. Short-term support has been established near the $780 to $810 range, with overhead resistance around its 52-week high of $999.00 [cite: 22, 43]. In the near term, the stock is expected to consolidate as market participants await the next operational update, which is scheduled for the fiscal first-quarter 2027 earnings release on August 5, 2026 [cite: 49].
STABLE BULLISH CONSOLIDATION
View McKesson Corporation (MCK) stock page
Loading the interactive version of this report…